Warning! FDA Is Flexing Its PMR Enforcement Muscle
The warning letter states that the recipient company failed to submit a required study protocol and final study report, pursuant to the company’s PMRs, and, therefore, the drug products are misbranded under the Federal Food, Drug and Cosmetic Act (FDCA).
This article will focus on the FDA’s general concerns and its enforcement approach rather...
To view the full article, register now.